Hikma Sees Signs Of A Bounceback For Generics
Now Forecasting Generics Sales Growth Of 20% In 2023, After Taking An 18% Hit In 2022
After a tough 2022 that saw Hikma suffer an 18% drop in generics sales – albeit mostly offset by growth in the firm’s injectables and branded divisions – the company has announced fresh forecasts for 2023 that suggest the generics segment will bounce back with growth of a fifth.
